Physician profile
Anita Shrestha Bhandari
NPI 1720811318
$3,753.87
in general payments reported to CMS, 2019-2025
17 companies · $3,754 in 2025
The $3,754 reported for 2025 was more than what 98% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $3,754.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,630 · Education: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,630.31 |
| Education | $123.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,060.66 | 2025 | |
| Janssen Biotech, INC. | $513.42 | 2025 | Tremfya |
| Madrigal Pharmaceuticals | $428.03 | 2025 | Rezdiffra |
| Phathom Pharmaceuticals, INC. | $306.27 | 2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $277.53 | 2025 | Xifaxan, Relistor |
| Ardelyx, INC. | $178.20 | 2025 | Ibsrela |
| Novo Nordisk INC | $158.67 | 2025 | Wegovy |
| Regeneron Healthcare Solutions, INC. | $155.06 | 2025 | Dupixent |
| Qol Medical, LLC | $137.88 | 2025 | Sucraid |
| Lilly USA, LLC | $117.35 | 2025 | Omvoh |
| Gilead Sciences, INC. | $108.24 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $99.61 | 2025 | Iqirvo |
| Aimmune Therapeutics, INC. | $71.82 | 2025 | Zenpep, Vowst |
| Genzyme Corporation | $71.18 | 2025 | |
| Intercept Pharmaceuticals, INC. | $31.99 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $22.01 | 2025 | Vegzelma |
| Takeda Pharmaceuticals U.S.A., INC. | $15.95 | 2025 | Entyvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anita Bhandari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.